Repair and recovery
Healing Peptides
Healing peptides are popular in recovery circles, but most claims sit far ahead of the human clinical evidence. The key SEO and research distinction is preclinical promise versus proven outcomes.
- Peptides covered
- 4
- Highest evidence
- 3/5
- Approved entries
- 0
How to compare this category
This comparison separates mechanism and animal repair models from established human efficacy. Use it as a conservative map before reading the individual database pages.
- Do not treat animal tendon, gut or wound-healing models as proof of human outcomes.
- Look for direct human trials on the exact compound, not only related thymosin or repair biology.
- Give extra weight to safety and sourcing because research-only peptides do not have approved consumer dosing.
Evidence scale
Scores rate evidence quality for the listed research context. They are not recommendations, prescriptions or a safety ranking.
- Evidence 1/5
- Mechanistic rationale only; no meaningful outcome evidence.
- Evidence 2/5
- Mostly animal, ex vivo, cell, or indirect evidence.
- Evidence 3/5
- Limited human pharmacology or small clinical evidence.
- Evidence 4/5
- Investigational compound with human randomized or phase 2/3 evidence.
- Evidence 5/5
- Approved medication with substantial human clinical evidence.
| Peptide | Status | Evidence | Best for | Half-life | Actions |
|---|---|---|---|---|---|
| BPC-157 Synthetic gastric peptide | Research only | 2/5 Mostly preclinical evidence | Preclinical tendon, gut and tissue-repair research context Mostly animal and mechanistic evidence | Not well characterized in humans | |
| TB-500 Thymosin β4 derivative | Research only | 2/5 Indirect preclinical evidence | Thymosin beta-4 repair-biology comparison Indirect preclinical evidence; weak direct human evidence | Not well characterized | |
| Thymosin Beta-4 Endogenous actin-sequestering peptide (beta-thymosin family) | Research only | 3/5 Mechanistically strong, clinically narrow | General category comparison See detail page for context. | Short, dose-dependent ~1-2 hours (IV) | |
| VIP (Vasoactive Intestinal Peptide) Neuropeptide; VPAC1/VPAC2 receptor agonist | Investigational | 2/5 Weak / mixed | General category comparison See detail page for context. | ~1 minute (plasma) |
Healing & recovery peptide cards
BPC-157
Body Protection Compound-157
Preclinical tendon, gut and tissue-repair research context
Mostly animal and mechanistic evidence
TB-500
Thymosin Beta-4 fragment
Thymosin beta-4 repair-biology comparison
Indirect preclinical evidence; weak direct human evidence
Thymosin Beta-4
TB4, Tβ4
Thymosin beta-4 sequesters monomeric G-actin to regulate the actin cytoskeleton, enabling cell migration, angiogenesis and tissue repair, with an anti-fibrotic Ac-SDKP fragment.
Endogenous actin-sequestering peptide (beta-thymosin family)
VIP (Vasoactive Intestinal Peptide)
Aviptadil
VIP activates VPAC1 and VPAC2 receptors, raising intracellular cyclic AMP to drive vasodilation, smooth-muscle relaxation and immune modulation.
Neuropeptide; VPAC1/VPAC2 receptor agonist
Healing & recovery guides
Read the strongest related guides for this category before drilling into a single database entry.
FAQ
Which healing peptides are most commonly discussed?
BPC-157 and TB-500 are the two most common healing peptides in consumer discussions, but both have limited direct human outcome evidence.
Is BPC-157 proven for injury recovery in humans?
No. BPC-157 has preclinical and animal injury-model evidence, but robust human clinical efficacy and dosing are not established. A July 2026 FDA advisory committee vote recommended 503A compounding-list inclusion; that is not drug approval or proof of human recovery efficacy.
Is TB-500 the same as thymosin beta-4?
TB-500 is marketed as a thymosin beta-4 fragment or related peptide. Many claims rely on thymosin beta-4 biology rather than direct TB-500 human trials.
More peptide categories
Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.
CompareGrowth Hormone PeptidesCompare growth hormone peptides including ipamorelin, CJC-1295 and tesamorelin by GH-axis mechanism, approval status, half-life and evidence score.
CompareCognitive PeptidesCompare cognitive peptides such as Selank and Semax by mechanism, route, regional clinical history, evidence score and research limitations.
CompareLongevity PeptidesCompare longevity peptides by evidence quality, mechanism and practical research limits, starting with GHK-Cu and copper peptide data.
Compare